Evidence map›Paper›PMID 26830473›Full record

ArticleStem cell research & therapy2016

BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.

Saeed Alghamdi, Irfan Khan, Naimisha Beeravolu, Christina McKee, Bryan Thibodeau, George Wilson, G Rasul Chaudhry

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Inhibition of bromodomain regulates cellular senescence in pancreatic adenocarcinoma.International journal of clinical and experimental pathology · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. The emerging role of BET inhibitors in breast cancer.Breast (Edinburgh, Scotland) · 2020
    Review
  16. NADPH Oxidase Inhibition in Fibrotic Pathologies.Antioxidants & redox signaling · 2020
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Saeed AlghamdiDepartment of Biological Sciences, Oakland University, Rochester, MI, 48309, USA. soalgham@oakland.eduff.
Irfan KhanDepartment of Biological Sciences, Oakland University, Rochester, MI, 48309, USA. irfan_khan2009@yahoo.com.
Naimisha BeeravoluDepartment of Biological Sciences, Oakland University, Rochester, MI, 48309, USA. nbeeravo@oakland.edu.
Christina McKeeDepartment of Biological Sciences, Oakland University, Rochester, MI, 48309, USA. cmmckee@oakland.edu.
Bryan ThibodeauBeaumont Health System, Royal Oak, MI, 48073, USA. Bryan.Thibodeau@beaumont.org.
George WilsonOU-WB Institute for Stem Cell and Regenerative Medicine, Oakland University, Rochester, MI, 48309, USA. George.Wilson@beaumont.edu.
G Rasul ChaudhryDepartment of Biological Sciences, Oakland University, Rochester, MI, 48309, USA. chaudhry@oakland.edu.
Oakland University · USBeaumont Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEfficacy and safety of anticancer drugs are traditionally studied using cancer cell lines and animal models. The thienodiazepine class of BET inhibitors, such as JQ1, has been extensively studied for the potential treatment of hematological malignancies and several small molecules belonging to this class are currently under clinical investigation. While these compounds are well known to inhibit cancer cell growth and cause apoptosis, their effects on stem cells, particularly mesenchymal stem cells (MSCs), which are important for regeneration of damaged cells and tissues, are unknown. In this study we employed umbilical cord derived MSCs as a model system to evaluate the safety of JQ1.

methodsCord derived MSCs were treated with various doses of JQ1 and subjected to cell metabolic activity, apoptosis, and cell cycle analyses using MTT assay, Annexin-V/FITC and PI staining, and flow cytometry, respectively. The effect of JQ1 on gene expression was determined using microarray and quantitative real-time reverse transcriptase polymerase chain reaction analysis. Furthermore, protein expression of apoptotic and neuronal markers was carried out using western blot and immunostaining, respectively.

resultsOur results showed that JQ1 inhibited cell growth and caused cell cycle arrest in G1 phase but did not induce apoptosis or senescence. JQ1 also down-regulated genes involved in self-renewal, cell cycle, DNA replication, and mitosis, which may have negative implications on the regenerative potential of MSCs. In addition, JQ1 interfered with signaling pathways by down regulating the expression of WNT, resulting in limiting the self-renewal. These results suggest that anticancer agents belonging to the thienodiazepine class of BET inhibitors should be carefully evaluated before their use in cancer therapy.

conclusionsThis study revealed for the first time that JQ1 adversely affected MSCs, which are important for repair and regeneration. JQ1 specifically modulated signal transduction and inhibited growth as well as self-renewal. These findings suggest that perinatal MSCs could be used to supplement animal models for investigating the safety of anticancer agents and other drugs.

Indexed as

ApoptosisAzepinesBromodomain Containing ProteinsCell Cycle ProteinsCell DifferentiationCell ProliferationCells, CulturedGene ExpressionHumansMesenchymal Stem CellsNuclear ProteinsProtein Serine-Threonine KinasesRNA-Binding ProteinsTranscription FactorsTriazolesWnt Signaling PathwayAzepinesBRD2 protein, humanBRD3 protein, humanBRD4 protein, humanBRDT protein, humanBromodomain Containing ProteinsCell Cycle Proteins(+)-JQ1 compoundNuclear ProteinsProtein Serine-Threonine KinasesRNA-Binding ProteinsTranscription FactorsTriazoles

Identifiers

PMID26830473
PMCPMC4736146
OpenAlexW2264130542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.